Relay Therapeutics, Inc.’s RLAY share price has dipped by 6.00%, which has investors questioning if this is right time to buy.

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple ...

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

Professor Yimin Zou and colleagues have published surprising results that reveal that RYK expression inhibits wound healing, ...

School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China ...